Kemwell’s 15,000 sq. m state-of-the-art facility, designed and developed in collaboration with Boehringer Ingelheim, offers world-class infrastructure and capabilities, including: Process Development & Characterization: Expertise in developing processes for complex biologics such as monoclonal antibodies (mAbs), bispecific and trispecific antibodies, fusion proteins and biosimilars Analytical Development: Development, qualification and validation of in-process and release tests for biologics. Formulation Development: Development of liquid and lyophilized formulations, and high-concentration protein formulations. Performing stability studies to confirm the final formulation. Manufacturing Capabilities: Over 5,000 L mammalian cell culture capacity for cGMP drug-substance manufacturing, along with sterile fill-finish facilities for both vials and prefilled syringes (PFS) for drug-product manufacturing.
Diksha Gupta is the Head of Business Development at Kemwell Biopharma, a global biologics CDMO, where she drives strategic partnerships and helps clients develop and scale complex biologics programs.
She has over 17 years of professional experience in the U.S., with hands-on expertise in end-to-end biologics development, including recombinant proteins, mAbs, multispecific antibodies, and biosimilars, gained through her roles at Pfizer and Bristol Myers Squibb.
She also held global product management and commercialization roles at Thermo Fisher Scientific, Danaher, and Bio-Techne.
Kemwell Biopharma works with a diverse portfolio of global biotech and pharmaceutical companies, ranging from emerging and mid-size biotechs to established multinational organizations who are seeking CDMO services